



美洲華人生物科學學會



Society of Chinese Bioscientists in America

December 2022

Newsletter Editor: Kunxin Luo, Ph.D.

NEWSLETTER

Volume 38 | Issue 4

CONTENTS

1. Letter from the SCBA President
2. Letter from the SCBA Secretary
3. Awards and Honors of SCBA Members
4. Donation Announcement
5. New SCBA-Genomic Maintenance Division
6. Update from the SCBA-Hepatology Division
7. Update from the SCBA- Boston (BBB) Chapter
8. Update from the SCBA-Virology Division
9. Update from the SCBA-Washington DC-Baltimore Chapter
10. Update from the SCBA-Neuroscience Division
11. New Membership List

Letter from the SCBA President

Dear SCBA colleagues and friends:

I wish you all a happy and productive new year in 2023!

I would like to congratulate Dr. [Chuan He](#) at the University of Chicago for winning the [2023 Wolf Prize in Chemistry](#). In addition, five members of our SCBA have been elected fellows of [AAAS' 2022 class](#). Congratulations!

One important mission of SCBA is to bridge our members for networking and collaboration. To help achieve this goal, SCBA has recently established **3 new chapters** in 2022, with a few others in progress. On

December 17, I had an opportunity to meet with the current Division and Chapter Presidents for the second time in 2022, and we brainstormed some ideas and possible initiatives. I wish to thank these leaders of [Divisions and Chapters](#) for their tireless work and contributions to SCBA, and we also would love to hear from our members for opinions and ideas. Please feel free to reach out to us.



SCBA Chapter and Division President Meeting
December 17, 2022

In the last few months, SCBA has been working with our members and organizations, including [Asian American Scholar Forum](#) (AASF) and [APA Justice](#) (APAJ), to address the unfair treatment of Chinese American scientists in the US by NIH and FBI by co-signing a series of petitions and open letters. In addition, I had an opportunity to attend the 13th [Chinese Biological Investigators Society \(CBIS\)](#) Biennial Conference in Las Vegas, and in the meeting, I updated current status by providing some NIH source numbers and discussed with

colleagues about future collaborations. I will continue updating in future newsletters.

Here we want to offer our most sincere appreciations to our [donors and sponsors](#) who have supported SCBA over the years. One exciting gift in 2022 is from Dr. [Louise Chow](#) and her husband Dr. [Tom Broker](#). Drs. Chow and Broker are world renowned molecular virologists and have played major roles in our understanding of human papillomavirus (HPV) replication and pathogenesis – see details in this newsletter. Thank you Dr. Chow and Dr. Broker for your generous support of SCBA!

In this issue of newsletter, you will also find a list of **175** newly jointed members of SCBA since 2022. Welcome aboard!

Shan-Lu Liu, MD, PhD
President
SCBA



Letter from the SCBA Secretary

Dear SCBA Members:

It has been an honor and pleasure for me to serve the SCBA as Secretary in the past year, along with Dr. Shan-Lu Liu, the President, and Dr. Pan Zheng, the Treasury. As the Secretary, I am responsible for editing the quarterly newsletter and supporting the President and the team in any way I can.

Our SCBA leadership team started at the beginning of 2022, just as the world being hit by the outbreak of SARS-CoV-2 Omicron, which is fortunately much less pathogenic, almost bringing our life back to normal. With

the full support of the SCBA Council, our team assisted the former President Dr. **Hui Zheng** to organize the 18th SCBA symposium in Boston in July 2022. This symposium was a major success with over 300 registered attendees. Prior to the Symposium, the members also elected the next SCBA leadership team (starting 2024) with Dr. **Lishan Su** as President-elect, **Shan Zha** as Secretary-Elect, and **Cynthia Ju** as Treasurer-Elect. This symposium also helped to expand SCBA membership among young and established biologists. We are so grateful to the hard work of the membership committee chaired by **Xin Chen**, and by the end of 2022, we have 175 new members (listed in this newsletter) who joined us in 2022. Currently SCBA has over 2500 members.

To better integrate SCBA members in various locations and strengthen networking and scientific collaborations, we strived to establish more local chapters and divisions. In 2022, SCBA welcomed 3 new divisions or local chapters. These include the **Seattle Chapter**, the **Ohio Chapter**, and the **Northern California Chapter**. At the beginning of new year 2023, we also welcome a new **Division of Genomic Maintenance**. Together with [5 previous Chapters and 6 Divisions](#), SCBA now has **13** local chapters and/or divisions. These chapters and divisions are very active and have organized series of conferences, seminars along with other activities. They have played key roles in connecting our members and fostering collaborations.

In 2023, we will continue our efforts in establishing local chapters and divisions in order to strengthen the interactions among our members. Targeted areas include Southern California, North Carolina, the research area of Cancer Biology, and so on. As one of the largest professional organizations of bioscientists in US, and certainly the biggest one for Chinese origin, the SCBA is

working with other organizations to unite the Chinese American bioscientists and represents our members. We love to hear your ideas and suggestions!

Finally, I would like to thank Dr. **Chris Lau** for his guidance and help with the Newsletter, as well as President **Shan-Lu Liu** for his leadership and support for all issues of SCBA Newsletters. I would also like to thank our division and chapter leaders for submitting their reports on their annual meetings, seminars, social

activities and other events to the Newsletter and your continuous support to SCBA.

Kunxin Luo, Ph.D.
Secretary
SCBA



Awards and Honors of SCBA Members

Dr. Chuan He awarded the 2023 Wolf Prize

We would like to congratulate Dr. **Chuan He** for



We are proud to announce
the 2023 Wolf Prize Laureate in Chemistry



Chuan He
The University of Chicago, USA

Prof. Chuan has been recognized
"For discovering reversible RNA methylation and its role in the regulation
of gene expression"

winning the highly prestigious Wolf Prize in Chemistry for his discovery of reversible RNA methylation and its important role in gene expression. Dr. He is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular

Biology at the University of Chicago and an investigator of the Howard Hughes Medical Institute.

Dr. He's research spans a broad range of fields including chemical biology, RNA biology, epigenetics, biochemistry, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. In 2011, his group discovered reversible RNA methylation as a new mechanism of gene expression regulation. His laboratory characterized the RNA m⁶A methyltransferase complex and several key reader proteins that bind preferentially to m⁶A-modified RNA and regulate their stability and translation. In 2020, Dr. He's laboratory discovered prevalent m⁶A methylation on chromatin-associated regulatory RNAs (carRNAs), which regulates chromatin state and global transcription. The reversible methylation of carRNA controls mammalian and plant development. His laboratory has spearheaded the development of enabling technologies to study the biology of RNA and DNA modifications. Thus, his research spans both chemistry and biology, and Dr. He has been an active participant in several SCBA conferences.

Multiple SCBA members elected as 2022 AAAS

Fellows

We congratulate the following SCBA members for being elected as 2022 AAAS fellows:

Dr. **Xin Chen** (Johns Hopkins University)
 Dr. **Paul Liu** (NIH-NHGRI)
 Dr. **Zhenkun Lou** (Mayo Clinic)
 Dr. **Lijun Rong** (U. of Illinois College of Med)
 Dr. **Guo-li Ming** (U. of Pennsylvania)
 Dr. **Xiufeng Wan** (U. of Missouri-Columbia)

Among these SCBA lifetime members, **Paul Liu** was the SCBA President in 2018-2019, an SCBA Council Member in 2014-2017 and the President of the Washington DC-Baltimore chapter in 2009. Dr **Xin Chen** is currently Chair of the SCBA Membership Committee. *If we have missed any SCBA members, please contact us via webmaster@scbasociety.org*



Xin Chen



Paul Liu



Zhenkun Lou



Guo-li Ming



Lijun Rong



Xiufeng Henry Wan

Donation Announcement

The SCBA is honored and thrilled to receive a generous donation from Dr. **Louise Chow** and Dr. **Thomas Broker**.

Dr. Chow is a Professor in the Department of Biochemistry and Molecular Genetics at University of Alabama at Birmingham and is a foreign associate with the US National Academy of Sciences. She is known for her research on the human papillomavirus (HPV). Dr. Chow has developed a procedure to produce large quantities of HPV, and investigated the entire replicative


cycle of HPV-18. Her work has made important contributions to our understanding of HPV and its relevance to human diseases including cancer, cystic fibrosis and AIDS. Dr. Chow also contributed to the discovery of gene splicing.

Dr. Chow attended the 18th SCBA symposium in Boston in July 2022 and gave a Keynote Speech on her lifetime work on the biology and pathology of HPV.

We are extremely grateful to Drs. Chow and Broker for their generosity and support for SCBA.

New SCBA-Division of Genome maintenance

The SCBA board of directors has approved the establishment of a new division: the Division of Genome Maintenance. Members in the division study mechanisms of genomic maintenance including DNA repair, DNA replication, checkpoint response, epigenetics, mitosis, chromosome stability, and associated diseases. The division currently has over 90 members and is expected to significantly expand its membership in multiple countries. Planned activities include virtual seminars and in-person meetings.



Dr. **Bing Xia** at Rutgers and Dr. **Zhenkun Lou** at Mayo Clinic are currently serving as Division contacts. Dr. Xia is a Professor of Radiation Oncology at Rutgers Cancer Institute of New Jersey. He is internationally recognized for his discovery of the PALB2 tumor suppressor and the establishment of the BRCA1-PALB2-BRCA2 DNA damage response and tumor suppression pathway. Dr. Lou is the Swanson/Schmucker Endowed Professor of Cancer Research and Chair of the Division of Oncology Research at Mayo Clinic. He is a well-known expert on the study of DNA double-strand repair and DNA replication stress pathways and has recently been elected an AAAS fellow.

Update from the SCBA-Hepatology Division

The 5th Annual Symposium of the SCBA-Hepatology Division and Chinese American Liver Society (CALS)

The 5th Annual Symposium of the SCBA-Hepatology Division and CALS was successfully held virtually on October 21-22, 2022, and in person on November 5 in Washington DC. Over 170 registrants and invited speakers from North America and China attended this exciting virtual event and close to 50 participants joined the in-person workshop and dinner. The participants were composed of faculty, postdoctoral fellows and graduate students from both basic and clinical fellows and graduate students from both basic and clinical science disciplines.



The meeting was organized by Dr. **Cynthia Ju** (President of SCBA – Hepatology Division) from McGovern Medical School, UT Health Houston, and assisted by Dr. **Grace Guo** (Secretary of SCBA – Hepatology Division) from Rutgers University, Dr. **Wen-Xing Ding** (President Elect) from University of Kansas Medical Center, Dr. **Lisa Zhang** (Treasurers of SCBA –

Hepatology Division) from University of Kansas Medical Center, and 7 other executive council members of the SCBA – Hepatology Division.

This two-day virtual meeting was featured by a keynote speech by Dr. **Jiandie Lin** from the University of Michigan on Liver Microenvironment in NASH and NASH-associated liver cancer. The symposium consisted of the following major sessions: Liver Physiology, Liver Disease – Basic & Translational, Non-alcoholic fatty liver disease, Liver Cancer – Basic & Translational, and Poster Presentation. Twenty-two plenary speakers including 10 short-talk speakers selected from abstracts presented with excellent talks. In the Poster Presentation session, abstracts were assigned to six parallel sessions for oral presentation that covered a wide range of liver diseases, including alcoholic liver disease, non-alcoholic fatty liver disease, liver injury, liver metabolism and liver cancer. The research covered by the keynote speaker, general session speakers or poster presenters was fantastic. The attendees actively participated in the scientific discussions. The meeting was partially sponsored by Research Diets and Gastroenterology. The society also received many personal donations from SCBA members and other liver researchers.

The organizers received a total of 69 abstracts. Each abstract was blindly reviewed by 3 experts from the Executive Council Committee of SCBA – Hepatology Division. Based on the ranking of the average scores, the top scorers among trainees were selected to receive an award. Thirty-nine junior investigators were granted the Postdoctoral Fellow and Graduate Student Research awards. The Life-long Achievement Award in Liver Research was presented to Dr. **John Chiang** from the Northeast Ohio Medical University.

At the end of the meeting, the new leadership for 22-23 was announced by Dr. **Cynthia Ju**. Dr. **Wen-xing Ding** is the new President and Dr. **Yanqiao Zhang** is the President-Elect.

Update from the SCBA-Boston Chapter

Update from SCBA-Boston Chapter (Boston Biology and Biotechnology Association)

The SCBA Boston Chapter - Boston Biology and Biotechnology Association (SCBA-BBB) has established its new leadership that comprises four core members: Dr. **Hong Chen** as President, Dr. **Kaifu Chen** as Communication Director, Dr. **Jingyan Han** and Dr. **Qiaobing Xu** both as Programming Director for the term 2023-2024.




Hong Chen.
President



Kaifu Chen
Communication
Director



Jingyan Han
Programming
Director




Qiaobing Xu
Programming
Director

The new leadership team has already been actively planning for the first event for 2023 -- The Second Annual Spring Symposium, a premier multidisciplinary translational medical conference, being held in the Boston Longwood area on February 25th, 2023. Among the highlights of this symposium are Dr. **Lee Zou's** farewell lecture and Dr. **Hao Wu's** award lecture. Please stay tuned for the detailed report on this exciting event in our next issue of the newsletter.

Update from the SCBA-Virology Division

The SCBA-Virology Division is proud to announce the recipients of 2022 ACVA Distinguished Scholar Award and 2022 ACVA Junior Investigator Award.

Dr. Shan Lu (卢山) is the recipient of 2022 ACVA (Association of Chinese Virologists in America, aka SCBA-Virology) Distinguished Scholar Award, in recognition of his outstanding scientific achievements and services to Chinese American scientists' community as well as the greater communities.



Dr. Lu is currently a Professor Emeritus at University of Massachusetts Medical School, and Chair, Board of Directors of International Society for Vaccines (ISV). He is well known as a world leader in vaccine research and a pioneer of nucleic acid vaccines, who established and promoted the heterogeneous prime-boost vaccination theory in which two different types of vaccines are used to deliver the same pathogen antigens so as to induce maximal protective immune responses. This concept has been further validated in the current COVID-9 vaccination campaign. Dr. Lu is a key figure in HIV vaccine development and the first Chinese American scientist who brought an experimental HIV vaccine into human studies, which has shown promising clinical trial results. He has more than 200 scientific publications and co-authored in ~10 scientific books.

Besides being a scientist, Dr. Lu is also a US board certified physician with more than 20 years clinical

practice experience and currently serving as the Executive Director of UMMS Clinical Trial Program. He is the former President and current Board Chair of IAS. He has served as Chair of ISV Annual Congresses for multiple years, and an elected fellow of ISV and Fellow of American College of Physicians.

Dr. Lu has been serving as the Co-Editor-in-Chief of Emerging Microbes & Infections (EMI) since 2012. He is an active member of several leading virology and vaccine journals including Journal of Virology, Current Opinion in Virology, Vaccine, NPj-Vaccines, Human Vaccines & Immunotherapeutics. He is also a study section member or Chair of multiple grant review panels, including NIH and Gates Foundation in the areas of infectious diseases and vaccines.

The SCBA-Virology Division held a virtual ACVA Distinguished Scholar Award Ceremony for Dr. Shan Lu on December 17, 2022, in which Dr. Lu delivered a lecture titled "Heterologous Prime-Boost Vaccination: from COVID-19 to HIV".

Dr. Liang Shan (单梁) is the recipient of 2022 ACVA Junior Investigator Award, in recognition of his significant accomplishments in virology research and career development.



Dr. Shan is currently an Assistant Professor at Washington University School of Medicine. His lab is focused on the immunobiology of HIV infection with a goal to train human immune system to better control or

clear HIV-1 infection. Shortly becoming independence, his group discovered CARD8 as an inflammasome sensor for HIV-1 protease (PR) activity, which was published in the journal of *Science*. They found that CARD8 can be activated via direct proteolysis of its N-terminus by HIV PR, creating an unstable neo-N-terminus. This, in turn, triggers its proteasomal degradation to release its bioactive C-terminus, leading to caspase 1 activation and pyroptosis. HIV-1 evades CARD8 sensing in host cells because PR remains inactive as a subunit of Gag–Pol polyprotein prior to viral budding. Dr. Shan's group further demonstrated that a class of anti-HIV drugs, NNRTI, can activate HIV PR through binding to the Gag–Pol. Treating HIV-infected macrophages and CD4+ T cells with NNRTIs leads to rapid pyroptotic cell death. This strategy holds promise to clear HIV reservoirs after virus reactivation.

Dr. Shan's group also generated novel mouse models that contain multiple human gene knock-ins to improve human hematopoiesis and maturation of human immune cells in the mouse system. Compared to commonly used humanized mouse models, the new models support functional development of human macrophages, NK cells, and memory T cells in tissues, which allow his lab to study the following topics: 1) control of HIV-1 infection by NK cells; 2) roles of tissue macrophages in HIV-1 infection, latent viral reservoirs, and innate immune sensing; 3) antibody Fc-receptor functions; 4) transcriptional and metabolic reprogramming of HIV-1 reservoirs in CD4+ T cells.

Within short 4 years as an Assistant Professor, Dr. Shan has published several seminal papers in the HIV field, including *Science*, *Journal of Clinical Investigation* and *Nature Chemical Biology*. His lab

continues to investigate the molecular basis of CARD8 and HIV PR interaction, as well as the development of CARD8-based HIV cure strategies.

The SCBA-Virology Division held a virtual seminar for the ACVA Junior Investigator Award on January 26, 2023, where Dr. Shan delivered a lecture titled “The CARD8 Inflammasome in HIV Pathogenesis and Viral Persistence”.

Update from the SCBA-Washington DC-Baltimore Chapter

The 2022 SCBA Washington DC-Baltimore Chapter Annual Scientific Symposium

The SCBA Washington DC-Baltimore Chapter held its annual scientific symposium on December 10, 2022, at the University of Maryland in College Park, Maryland. The symposium was successfully organized by Dr. **Mitchell Ho** of the National Cancer Institute (NCI), NIH and Dr. **Xin Chen** of Johns Hopkins University.

Dr. **Zhe Han** (University of Maryland School of Medicine), President of the SCBA-Baltimore Chapter, made opening remarks. The scientific program has three scientific sessions, a poster session, and two career discussion panels. Dr. **Kun-Liang Guan** of the University of California San Diego delivered an outstanding keynote lecture entitled “The Hippo Pathway: Signaling and Cancer”. The first session on studies using model organisms was co-chaired by Dr. **Yunbo Shi** (NIH) and Dr. **Zhe Han**. Dr. **Meng Wang** (Janelia Research Campus, HHMI), Dr. **Xiaoyan Zheng** (George Washington University), Dr. **Jiefu Li** (Janelia Research Campus, HHMI) and Dr. **Wei Li** (NIH) were invited to

give lectures. Dr. **Zhaoyi Peng** (NIH/NICHD) was selected to give a short talk. The second session on biomedical engineering and structural biology was co-chaired by Dr. **Yihong Ye** (NIH/NIAID) and Dr. **Tongqing Zhou** (NIH/NIAID). Dr. **Xiongyi Huang** (Johns Hopkins University), Dr. **Jinwei Zhang** (NIH/NIDDK) were invited to give lectures. Dr. **Yanxin Liu** (University of Maryland) was selected to give a short talk. The third session on therapeutic strategies against diseases was co-chaired by Dr. **Xinwei Wang** (NIH/NCI) and Dr. **Feng Qian** (University of Maryland). Dr. **Lichun Ma** (NIH/NCI), Dr. **Heng Zhu** (Johns Hopkins University) and Dr. **Shuo Gu** (NIH/NCI) were invited to give lectures. Dr. **Zhijian Duan** (NIH/NCI) was selected to give a short talk. Dr. **Roland Owens** (NIH Office of Intramural Research), Dr. **Mitchell Ho** and Dr. **Xin Chen** served as panelists in the Academic Career Panel. Dr. **Pan Zheng** (OncoC4, Inc.) and Dr. **Angela Zeng** (AstraZeneca) served as panelists in the Industry Career Panel. Both panels have attracted many participants.



In addition to the three abstracts selected for short talks, six poster presenters were selected for the Best Poster Award including Drs. **Dan Li, Yue Xu, Nan Li, Binbin Ma, Ainslee Zou and Ching-Wen Chang**. The

abstract selection committee consisted of seven faculty members from the NIH and local universities. Finally, Dr. **Mitchell Ho**, the president-elect gave closing remarks. The 2022 SCBA DC-Baltimore Chapter symposium was a great success.

Update from SCBA-Neuroscience Division

On behalf of the SCBA and the Society of Chinese Neuroscientists (SCN), Dr. **Zhiping Pang** and Dr. **Dong Sun** hosted a Chinese Scholar Satellite Social Event for Chinese students and scholars in neuroscience during the 2022 annual meeting of the Society for Neuroscience (SfN) on November 12, 2022. The event was held at Marriott Marquis Marina Hotel in San Diego. The event attracted about 300-500 meeting participants - most of them are Chinese students and scholars but a significant number of neuroscientists from other countries (see attached photos).



At this event, we had three speakers. Dr. **John Ngai**, Director of the NIH's Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative, gave

a keynote speech about the blueprint of the NIH effort in brain research. The director of NIH NINDS, Dr. **Walter J. Koroshetz**, and the director of the NIH National Eye Institute, Dr. **Michael Chiang**, attended the event. Dr. **Lin Mei** and Dr. **Dandan Sun** also gave short speeches about the development of neuroscientists with Chinese ancestry and how we can integrate with other communities to contribute more to neuroscience research. This exciting event provides an opportunity for neuroscience students and scholars from different areas (academia and industry) to interact and establish potential collaboration. More importantly, this event also offers a venue for young students and trainees to learn from established scientists in academia and industry.

2022 New SCBA members

We are happy to welcome the following new members who joined SCBA in 2022:

Mario Alba,	USC
Gianfranco Alpini,	Indiana University
Xiaochen Bai,	UT Southwestern Medical Center
Bishuang Cai,	Icahn School of Medicine at Mount Sinai
Yaqiang Cao,	NHLBI/NIH
Guanming Chen,	FDA
Xi Chen,	Baylor College of Medicine
Xin Chen,	Johns Hopkins University
Shi-Jie Chen,	University of Missouri
Fangzhou Cheng,	Boston University School of Medicine
Zhongbin Deng,	University of Louisville
Yuanhua Ding,	ALLIANTHERA Boston, Inc
Bingning Dong,	Baylor college of medicine
Zhenhao Fang,	Yale University
Yun Fang,	The University of Chicago
Jing Fang,	Houston Methodist Hospital

Zongdi Feng,	The Research Institute at Nationwide Children's Hospital
Yaojie Fu,	NIAAA, NIH
Fei Gao,	ITI, Stanford University
Xinlei Gao,	Boston Children's Hospital
Yang Gao,	Rice University
Chunyang Gu,	UW-Madison
Shanqing Gu,	ExonanoRNA, LLC
Shuo Gu,	National Cancer Institute
Chen Gu,	The Ohio State University
Lijie Gu,	OUHSC
Qian Guo,	Temple University
Grace Guo,	Rutgers University
Gang Han,	University of Massachusetts-Medical School
Jingyan Han,	Boston University
Peijian He,	Emory University
Yukai He,	Medical College of Georgia,
	Augusta University
Yanlin He,	Pennington Biomedical Research Center
Yuan He,	Northwestern University
Zakiyah Henry,	Rutgers University
Wenzhe Ho,	Temple University
Jiakai Hou,	University of Houston
Yi-Ping Hsueh,	Institute of Molecular Biology, Academia Sinica
Qianqian Hu,	Moffitt Cancer Center
Wenhui Hu,	Temple University LKSOM
Hailiang Huang,	Massachusetts General Hospital
Michael Huen,	The University of Hong Kong
Hongpeng Jia,	Johns Hopkins University School of Medicine
Lin Jia,	The University of Texas at Dallas
Li Jia,	Brigham and Women's Hospital
Xiaosong Jiang,	UC Davis
Zhenghui Jiang,	Beth Israel Deaconess Medical Center
Ningling Kang,	University of Minnesota
Lindsey Kennedy,	Indiana University School of Medicine
Bilon Khambu,	Tulane University
Bo Kong,	Rutgers University
Xia Lei,	Oklahoma State University
Justin Leung,	University of Arkansas for Medical Sciences
Xiaohong Li,	College of Medicine and Life Sciences, The University of Toledo
Chunying Li,	Georgia State University
Wei Li,	Children's National Hospital


Yanqiang Li, Zihai Li,	Boston Children's Hospital Pelotonia Institute for Immuno- Oncology, Ohio State University Janelia Research Campus, HHMI Emory University School of Medicine	Hui Qian,	University of Kansas Medical Center
Jiefu Li, Bo Liang,	Stanford University University of Massachusetts Medical School	Li Qiang, Zepeng Qu, Jianwen Que, Ping Ren,	Columbia University NIH/NEI Columbia University University of Texas Medical Branch
Xueqiu Lin, Honghuang Lin,	Mayo Clinic University of Maryland Baltimore Harvard school of dental medicine Tulane University	Hongxia Ren, Xiangbo Ruan, Ekihiro Seki, Charlie Sheen, Yin Shen,	Indiana University Johns Hopkins School of Medicine Cedars-Sinai Medical Center Promega University of California, San Francisco
Mengfei Liu, Kaiyan Liu, Yuchen Liu, Gang Liu, Ming Liu, Xiangyu Liu, Mengmeng Liu, Xiaole Shirley Liu, Huiping Liu, Yanxin Liu,	North Carolina State University Harvard University Tulane University GV20 Therapeutics Northwestern University University of Maryland College Park	Honglue Shen, Hailing Shi,	Merck Broad Institute of MIT and Harvard
Wanqing Liu, Jiandong Liu, Tao Liu,	Wayne State University University of North Carolina Brigham and Women's Hospital in Harvard Medical School	Xiaotong Song, Bangyan Stiles, Hua Su, Shang Su, Shengyi Sun, Wei Sun,	Texas A&M University University of Southern California UCSD The University of Toledo Wayne State University University of Pittsburgh Medical Center
Xiaoqi Liu, Shixin Liu, Shao-Hua Lo, Jonathan Long, Qingchun Lu, Shaolei Lu,	University of Kentucky The Rockefeller University TFBS Bioscience Inc. Stanford University Temple University Alpert Medical School of Brown University	Shi-Yong Sun,	Emory University School of Medicine
Yong Lu, Kunxin Luo, Xiaowen Ma,	Houston Methodist Hospital University of California, Berkeley University of Kansas Medical Center	Qi Tang, Yizhi Tao, Taojian Tu, Xueping Wan, Liling Wan, Xiu-Feng Wan, Bo Wang, Hong Wang, Qihong Wang, Yuan Wang,	University of Southern California Rice University University of Southern California Boston University UPenn University of Missouri-Columbia Virginia Tech North Carolina State University The Ohio State University Boston Children's Hospital, Harvard Medical School
Qian Ma, Lichun Ma, Xiaochao Ma, Shenglin Mei, Jianquan Ni, Shunbin Ning, Li-Mei Pai, Huadong Pei, Yihan Peng, Guang Peng,	Tufts University NIH University of Pittsburgh Massachusetts General Hospital Tsinghua University East TN State University Chang Gung University Georgetown University Georgetown University The University of Texas MD Anderson Cancer Center	Da-Zhi Wang, Zilai Wang, Nicole Wang, Xin Wang, xu wang, Jiang Wang,	University of South Florida UIC Baylor College of Medicine Boston Children's hospital Temple University University of Cincinnati College of Medicine
Xianhua Piao, Lei Qi,	University of California, San Francisco Stanford University	Hua Wang, Yankai Wen, Yingying Wu, Xiangdong Wu,	The Lundquist Institute at Harbor- UCLA UTHealth Harvard University University of Maryland School of Medicine

Fen Xia,	University of Arkansas for Medical Sciences	Chongzhi Zang,	University of Virginia
Bing Xia,	Rutgers University	Chen Zhang,	University of Kansas Medical Center
Ying Xie,	Tufts University	Huaiying Zhang,	Carnegie Mellon University
Mei Xin,	Cincinnati Children's Hospital Medical Center	Yiying Zhang,	Massachusetts General Hospital, Harvard Medical School
Hongjiao Xu,	Boston Children's Hospital	Chaolin Zhang,	Columbia University
Han Xu,	MD Anderson Cancer Center	Yi Zhang,	Harvard University
Allison Xu,	University of California, San Francisco	Wei Zhang,	Yale University
Pingwen Xu,	The University of Illinois at Chicago	Shaun Zhang,	University of Houston
Shengmin Yan,	Tulane University School of Medicine	Ye Zhang,	University of California Los Angeles
Hao Yan,	Harvard Medical School & MGH	Rui Zhao,	University of Colorado Anschutz Medical Campus
Shan Yan,	University of North Carolina at Charlotte	Jun Zhao,	Cleveland Clinic Florida Research and Innovation Center
Qin Yan,	Yale University	Na Zhao,	Mayo Clinic Florida
Yang Yang,	University of Texas Health Science Center at Houston	Xiaolan Zhao,	Memorial Sloan Kettering Cancer Center
Ming Yang,	University of Missouri	Bin Zheng,	Massachusetts General Hospital
Xiaoqiu Yang,	Boston University	Zhi Zhong,	Medical University of South Carolina
Zhenning Yang,	Rutgers University	Yuxiang Zhou,	Boston University School of Medicine
JingYang,	University of California, San Diego	Liqin Zhu,	St. Jude Children's Research Hospital
Linxiang Yin,	Harvard University	Wei-Xing Zong,	Rutgers University
Jun Yin,	Georgia State University	Chenghang Zong,	Baylor College of Medicine
Jindan Yu,	Northwestern University		

A welcome note from Executive Directors to new members

The Society of Chinese Bioscientists in America (SCBA) is the largest professional society for Chinese bioscientists outside of China. Our SCBA network has continued to expand, and we hope that our members encourage colleagues to join and enjoy the many resources and opportunities at SCBA.

We would like to give a warm welcome to our newest members.



Xi He, Ph.D.
Co-Executive Director



Chris Lau, Ph.D.
Co-Executive Director

2-Year
IMPACT
FACTOR
9.606

Cell & Bioscience

Official journal 美洲華人生物科學學會
Society of Chinese Bioscientists in America

5-Year
IMPACT
FACTOR
8.113

Editorial Board

Editor-in-Chief

Yun-Fai Chris Lau

University of California, San Francisco
Genetics, Genomics and Epigenetics
Developmental Biology and Stem Cell

Associate Editor-in-Chief

Ying E Zhang

NCI, National Institutes of Health
Molecular and Cell Biology
Biochemistry and Structural Biology

Associate Editor-in-Chief

Dong Yan Jin

University of Hong Kong
Cancer Biology
Immunology, Microbiology, and Virology

Associate Editor-in-Chief

Lin Mei

Case Western Reserve University
Neuroscience
Physiology and Medicine

Editors

Jia Chen, Icahn School of Medicine at Mount Sinai, USA

Ruey-Hwa Chen, IBC, Academia Sinica, Taiwan

Wanjun Chen, NIDCR, National Institutes of Health, USA

Wen-Xing Ding, University of Kansas, USA

Zhe Han, University of Maryland, USA

Wanjin Hong, Institute of Molecular and Cell Biology, Singapore

Yi-Ping Hsueh, IMB, Academia Sinica, Taiwan

Jim Hu, University of Toronto, Canada

Peng Jin, Emory University, USA

Kwok Wai Lo, Chinese University of Hong Kong, Hong Kong

Kunxin Luo, University of California, Berkeley, USA

Duanqing Pei, Westlake University, China

Yun Qiu, University of Maryland, USA

Yufang Shi, Soochow University, China

Stephen H Tsang, Columbia University, USA

Xin Wei Wang, NCI, National Institutes of Health, USA

Linxin Wei, The Second Military Medical University, China

T-C Wu, Johns Hopkins University, USA

Yong Xu, Baylor College of Medicine, USA

Zhi-Ming Zheng, NCI, National Institutes of Health, USA

Huiping Zhou, Virginia Commonwealth University, USA

Impact Factors Through the Years

Year	Journal Impact Factor	JIF without Self Cites	5 Year Impact Factor
2021	9.606	9.535	8.113
2020	7.133	6.980	6.302
2019	5.026	4.921	4.443
2018	3.355	3.332	3.561
2017	3.405	3.314	3.566
2016	3.294	3.221	3.416
2015	2.883	2.649	3.188
2014	3.630	3.457	3.443
2013	3.210	2.988	3.210
2012	3.000	2.561	3.000

Cell & Bioscience is an open access, peer-reviewed journal that encompasses all areas of the life science research. Interested in organizing a special issue on a specific topic? Please contact the Editor-in-Chief and visit the journal website for details.



Cell & Bioscience

cellandbioscience.biomedcentral.com



BioMed Central
The Open Access Publisher
Part of Springer Nature